Contract research organisation (CRO) Rho has selected Dassault Systèmes company Medidata’s decentralised clinical trial (DCT) capabilities for patient-focused approach to new drug development.
The company is using Medidata’s end-to-end platform to standardise its clinical trial platform to build the technology offerings related to DCTs.
This decentralised approach will help its clients to attract and secure more sponsor bids.
It also helps in reducing study build time, accelerating data reconciliation and clean-up, and saving money on data migrations and transfers.
This will allow Rho to provide cross-study data in decentralised trials and enables quick reporting of cross-domain.
Medidata partner and senior vice-president Joan Shaiman said: “Forward-thinking CROs, such as Rho, are rapidly making the necessary platform and accreditation investments to enable sponsors to move into a hybrid and/or fully decentralised approach to managing clinical trials.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
The company’s single platform helps to provide flexible support for future business growth.
This clinical technology capability will provide the sponsors with complete access to their clinical and operational data, which will help in advancing efforts to accelerate their development programmes.
Rho CEO Dr Laura Helms Reece said: “By partnering with Medidata we are further committing to sponsors that we can meet and exceed their future needs, especially as the market evolves from traditional clinical trials toward a more decentralised and patient-focused approach.
“This investment will give us an important competitive advantage as we strive to be ahead of the curve, as the industry continues to evolve in response to advancing technologies and the need for greater diversity and inclusion in clinical trials.
“A key element will be streamlined, real-time visibility into patient data and quality metrics throughout a decentralised trial, from inception to study conclusion.”
The company provides a complete range of clinical research services across the entire drug development process.